24/7 Market News Snapshot 25 April, 2025 – Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV)

April 25, 2025

DENVER, Colo., 25 April, 2025 (www.247marketnews.com) – (NASDAQ:ACRV) are discussed in this article.
Acrivon Therapeutics, Inc. is currently experiencing a significant surge in its stock price, with shares trading at $2.615, reflecting an impressive increase of over 31% in pre-market trading. This rally is backed by a strong trading volume of approximately 3.23 million shares, illustrating heightened investor interest and potential for continued upward momentum. Technical indicators suggest a sustained bullish trend, making Acrivon a noteworthy consideration for investors in the biotech sector.

The company’s optimism is further bolstered by its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting, where it plans to showcase groundbreaking data from its proprietary Acrivon Predictive Precision Proteomics (AP3) platform. The presentation will focus on findings related to ACR-2316, a novel WEE1/PKMYT1 inhibitor that has displayed superior efficacy in preclinical studies compared to conventional therapeutic benchmarks. These findings underscore ACR-2316’s potential to induce tumor cell death more effectively, marking it as a promising candidate in the fight against various solid tumors.

Currently in a Phase 1 clinical trial, ACR-2316 has already progressed through three dose-escalation cohorts, achieving impressive results, including observable tumor shrinkage among patients. Notably, approximately 25% of patients exhibited tumor reduction after receiving a dose substantially lower than what is anticipated for Phase 2.

Peter Blume-Jensen, M.D., Ph.D., CEO and Founder of Acrivon Therapeutics, emphasized the significance of the design of ACR-2316 that targets key tumor pathways to optimize anti-cancer effects. With the rapid advancement of the Phase 1 study and promising early clinical activity, Acrivon is well-positioned to shape the future landscape of precision oncology, offering transformative solutions tailored to the individual needs of patients battling cancer.

Related news for (ACRV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.